Updated hourlyHourly refreshSun, Oct 25, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Healthcare
VANCOUVER, British Columbia, Oct. 24, 2026 -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRα-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
Oct 24 · 06:30·GlobeNewswire
Finance · Healthcare
Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8 PRAME cell therapy.
Oct 24 · 06:30·GlobeNewswire
Healthcare · Biotech & pharma
Lydian Cosmetic Surgery Clinic in Seoul details non-surgical stem cell injections for knee osteoarthritis, covering candidacy, process, costs and realistic limits on cartilage regeneration for international patients weighing treatment in Korea. -- Lydian Cosmetic Surgery Clinic in Seoul offers non-surgical stem cell injections for knee osteoarthritis, using cells collected from a patient's own fat tissue or bone marr
Oct 24 · 04:35·MarketersMEDIA
Healthcare · Biotech & pharma
The first patient dosing has been completed in phase 3 clinical study of JS203 (CD20/CD3 bsAb), in combination with chemotherapy in patients with R/R DLBCL
Oct 24 · 03:30·GlobeNewswire
Finance · AI
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today...
Oct 24 · 01:26·PR Newswire
Healthcare · Biotech & pharma
~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary Hyperparathyroidism (SHPT) on hemodialysis ~ Upacicalcet also reduced FGF23 and markers of bone turnover in the trial...
Oct 23 · 23:30·PR Newswire
Biotech & pharma
62% confirmed objective response rate and 12.2-month median duration of response in phase Ib trial
Oct 23 · 22:17·GSK
Finance · SaaS
MENLO PARK, Calif., October 23, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees. On October 19
Oct 23 · 21:00·Business Wire
Finance · AI
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology MIAMI & SEOUL, South Korea, October 23, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agre
Oct 23 · 20:37·Business Wire
Finance · Biotech & pharma
SAN FRANCISCO, Oct. 23, 2026 -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common...
Oct 23 · 20:15·PR Newswire
Finance · Healthcare
Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces...
Oct 23 · 20:05·PR Newswire